Cuorips Inc. Logo

Cuorips Inc.

Develops iPS cell therapies, like a cardiomyocyte sheet for severe heart failure.

4894 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
中央区日本橋本町三丁目11番5号 日本橋ライフサイエンスビルディング2、507
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cuorips Inc. is a regenerative medicine company engaged in the research, development, manufacturing, and commercialization of cell-based therapeutic products. The company specializes in advanced technologies involving induced pluripotent stem (iPS) cells. Its flagship development is the world's first iPS cell-derived cardiomyocyte sheet, a novel treatment targeting severe heart failure. In addition to its own product pipeline, Cuorips is involved in optimizing manufacturing and quality processes and offers contract development services to contribute to the broader advancement of medicine.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Cuorips Inc. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-06-25 08:39
Regulatory News Service
臨時報告書
Japanese 22.9 KB
2025-06-20 08:39
Regulatory News Service
確認書
Japanese 8.1 KB
2025-06-20 08:38
Regulatory News Service
内部統制報告書-第9期(2024/04/01-2025/03/31)
Japanese 21.5 KB
2025-06-20 08:37
Annual Report
有価証券報告書-第9期(2024/04/01-2025/03/31)
Japanese 2.3 MB
2024-11-14 02:30
Regulatory News Service
確認書
Japanese 8.1 KB
2024-11-14 02:24
Interim Report
半期報告書-第9期(2024/04/01-2025/03/31)
Japanese 162.2 KB
2024-07-01 02:38
Regulatory News Service
臨時報告書
Japanese 22.2 KB
2024-06-27 09:38
Regulatory News Service
内部統制報告書-第8期(2023/04/01-2024/03/31)
Japanese 21.2 KB
2024-06-27 09:37
Regulatory News Service
確認書
Japanese 8.1 KB
2024-06-27 09:36
Annual Report
有価証券報告書-第8期(2023/04/01-2024/03/31)
Japanese 2.9 MB
2024-02-13 07:36
Regulatory News Service
確認書
Japanese 8.1 KB
2024-02-13 07:36
Quarterly Report
四半期報告書-第8期第3四半期(2023/10/01-2023/12/31)
Japanese 132.3 KB
2023-11-10 08:29
Regulatory News Service
確認書
Japanese 8.2 KB
2023-11-10 08:23
Quarterly Report
四半期報告書-第8期第2四半期(2023/07/01-2023/09/30)
Japanese 153.3 KB
2023-08-10 09:08
Regulatory News Service
確認書
Japanese 8.2 KB

Automate Your Workflow. Get a real-time feed of all Cuorips Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Cuorips Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Pharmocann Global Ltd. Logo
Develops pharma-grade medical cannabis products like oils, ointments, tablets, and cosmetics.
Israel PMCN-M
Pherecydes Pharma Logo
Develops precision phage therapy to treat resistant bacterial infections.
France ALPHE
Philogen Logo
Developing targeted biopharmaceuticals for oncology using proprietary ligand-based delivery.
Italy PHIL
Photocure ASA Logo
Develops photodynamic pharmaceuticals and devices to enhance bladder cancer detection for urologists.
Norway PHO
Pierrel Logo
Global pharma company specializing in dental anesthetics and contract manufacturing services.
Italy PRL
Pluri Inc. Logo
Develops placenta-based cell therapeutics using a proprietary 3D cell-expansion platform.
Israel PLUR
Poltreg S.A. Logo
Pioneering T-regulatory cell therapies for autoimmune diseases like diabetes, MS, and ALS.
Poland PTG
PolyPeptide Group AG Logo
A global CDMO specializing in peptide and oligonucleotide APIs for pharma and biotech partners.
Switzerland PPGN
Psych Capital Plc Logo
A life sciences firm developing psilocybin treatments for anorexia and mental health conditions.
United Kingdom PSY
Pure Biologics S.A. Logo
Develops novel antibody & aptamer drugs for immuno-oncology and autoimmune diseases.
Poland PUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.